Sagimet Biosciences Inc. - Series A Common Stock (NQ:SGMT)

9.370 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sagimet Biosciences Inc. - Series A Common Stock

< Previous 1 2 3 4 5 6 Next >

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

August 01, 2024

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences to Host Conference Call and Webcast to Discuss Recently Presented Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat

June 10, 2024

Call scheduled on Thursday, June 13, 2024 at 9.30 AM PT / 12:30 PM ET

From Sagimet Biosciences Inc.

Via GlobeNewswire

What's Going On With Sagimet Biosciences Stock On Thursday? ↗

June 06, 2024

Sagimet Biosciences shared promising data from its FASCINATE-2 Phase 2b trial of denifanstat at the EASL Congress.

Via Benzinga

Sagimet Biosciences Presents Data from ITT and F3 Patient Population in Phase 2b FASCINATE-2 Clinical Trial of Denifanstat at EASL International Liver Congress 2024

June 06, 2024

From Sagimet Biosciences Inc.

Via GlobeNewswire

What's Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday? ↗

June 05, 2024

Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment....

Via Benzinga

Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday ↗

May 16, 2024

Via Benzinga

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024

May 16, 2024

Dr. Scott Friedman to present unmet need in MASH and discuss Sagimet’s topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH

From Sagimet Biosciences Inc.

Via GlobeNewswire

SGMT Stock Earnings: Sagimet Biosciences Beats EPS for Q1 2024 ↗

May 15, 2024

SGMT stock results show that Sagimet Biosciences beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

Sagimet Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 15, 2024

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Announces Oral Presentation of Data from the Phase 2b FASCINATE-2 Study of Denifanstat in MASH at EASL International Liver Congress 2024

May 07, 2024

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Announces Appointment of Thierry Chauche as Chief Financial Officer

May 06, 2024

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 3, 2024

April 22, 2024

Sagimet announced positive topline data from its FASCINATE-2 Phase 2b clinical trial of denifanstat in MASH in January 2024 and plans to initiate Phase 3 trial in the second half of 2024

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Announces Completion of Phase 1 Hepatic Impairment Study with FASN Inhibitor Denifanstat

March 27, 2024

From Sagimet Biosciences Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Intraday Session ↗

March 25, 2024

Via Benzinga

Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

March 25, 2024

Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.

Via Benzinga

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

March 25, 2024

From Sagimet Biosciences Inc.

Via GlobeNewswire

Sagimet Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

March 25, 2024

From Sagimet Biosciences Inc.

Via GlobeNewswire

Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy? ↗

March 17, 2024

Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.

Via The Motley Fool

Sagimet Biosciences to Participate in Two Upcoming Investor Conferences

February 29, 2024

From Sagimet Biosciences Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

February 16, 2024

Via Benzinga

Why FMC Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

February 06, 2024

Shares of FMC Corporation (NYSE: FMC) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter results.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

February 06, 2024

Via Benzinga

Week In Review: Arrivent BioPharma Raises $175 Million In IPO For In-Licensings From China ↗

January 27, 2024

ArriVent BioPharma priced its upsized Nasdaq IPO at $18 dollars per share, raising $175 million. The company’s stated goal is to find promising novel assets from China and other countries, which it...

Via Talk Markets

Topics Initial Public Offering

Why Intel Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

January 26, 2024

Shares of Intel Corporation (NASDAQ: INTC) fell sharply during Friday’s session. Intel reported upbeat results for its fourth quarter, but issued a weak forecast for the first quarter.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

January 26, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

January 26, 2024

Pre-market stock movers are worth checking out on Friday as we get into all of the biggest news affecting shares this morning!

Via InvestorPlace

KLA Reports Q2 Results, Joins Visa, Western Digital And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

January 26, 2024

U.S. stock futures were lower this morning, with the Dow futures falling around 100 points on Friday.

Via Benzinga

Topics Stocks

Sagimet Biosciences Announces Pricing of Public Offering of Series A Common Stock

January 25, 2024

From Sagimet Biosciences Inc.

Via GlobeNewswire

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

January 24, 2024

It's time to dive into the biggest pre-market stock movers on Tuesday with a breakdown of all the latest news affecting shares this morning.

Via InvestorPlace

Texas Instruments Reports Q4 Results, Joins BlackBerry And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

January 24, 2024

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Wednesday.

Via Benzinga

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.